Recurrent activating mutations in CD28 and CD28-CTLA-4 fusion proteins have been identified in T-cell leukemias and lymphomas, and these increase the ligands’ affinity and amplifying costimulatory signals that promote tumor immune escape [64,65]. This evidence concerns the gene CD28 and neoplasm.